MX2023010840A - Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. - Google Patents
Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.Info
- Publication number
- MX2023010840A MX2023010840A MX2023010840A MX2023010840A MX2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- related compositions
- activatable
- cytokine
- constructs
- Prior art date
Links
- 108090000695 Cytokines Proteins 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 238000006471 dimerization reaction Methods 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan en el presente documento construcciones de citocina activables que incluyen: (a) una primera construcción monomérica que comprende una primera máscara peptídica (PM1), un tercer resto escindible (CM3), una primera proteína de citocina madura (CP1), un primer resto escindible (CM1), y un primer dominio de dimerización (DD1), en donde la CM1 se sitúa entre la CP1 y la DD1, y la CM3 se sitúa entre la PM1 y la CP1; y (b) una segunda construcción monomérica que comprende una segunda proteína de citocina madura (CP2), un segundo resto escindible (CM2), y un segundo dominio de dimerización (DD2), en donde el CM2 está situado entre la CP2 y el DD2, en donde: el DD1 y el DD2 se unen entre sí; y donde la ACC se caracteriza por una reducción de al menos una actividad de la CP1 y/o CP2 en comparación con un nivel de control de la al menos una actividad de la CP1 y/o CP2.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163161913P | 2021-03-16 | 2021-03-16 | |
US202163164827P | 2021-03-23 | 2021-03-23 | |
US202163254748P | 2021-10-12 | 2021-10-12 | |
US202163276893P | 2021-11-08 | 2021-11-08 | |
PCT/US2022/020492 WO2022197764A2 (en) | 2021-03-16 | 2022-03-16 | Masked activatable cytokine constructs and related compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010840A true MX2023010840A (es) | 2023-10-26 |
Family
ID=81389111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023010840A MX2023010840A (es) | 2021-03-16 | 2022-03-16 | Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11667687B2 (es) |
EP (1) | EP4308594A2 (es) |
JP (1) | JP2024511387A (es) |
KR (1) | KR20230157448A (es) |
AU (1) | AU2022237504A1 (es) |
BR (1) | BR112023018735A2 (es) |
CA (1) | CA3211924A1 (es) |
IL (1) | IL305716A (es) |
MX (1) | MX2023010840A (es) |
TW (1) | TW202304958A (es) |
WO (1) | WO2022197764A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202334185A (zh) * | 2021-10-08 | 2023-09-01 | 美商Cytomx生物製藥公司 | 可經活化之細胞介素構築體和組合方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
EP1899368A2 (en) | 2005-05-26 | 2008-03-19 | Schering Corporation | Interferon-igg fusion |
WO2007105027A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US20100297081A1 (en) | 2007-12-18 | 2010-11-25 | Huang Yanshan | Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
WO2011123683A2 (en) | 2010-04-02 | 2011-10-06 | University Of Rochester | Protease activated cytokines |
CA2814595C (en) | 2010-12-03 | 2020-06-16 | Adamed Sp. Z O.O. | Anticancer fusion protein |
WO2012099886A1 (en) | 2011-01-18 | 2012-07-26 | Bioniz, Llc | Compositions and mehthods for modulating gamma-c-cytokine activity |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
EP3049111A2 (en) | 2013-09-25 | 2016-08-03 | Cytomx Therapeutics Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
EP4176896A1 (en) | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
GB201411506D0 (en) | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
MX2017005148A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
JP2019518786A (ja) | 2016-05-06 | 2019-07-04 | 牧林 王 | インターロイキンの組み合せ及びその使用 |
KR102649972B1 (ko) | 2016-10-14 | 2024-03-22 | 젠코어 인코포레이티드 | IL15/IL15Rα 이종이량체 Fc-융합 단백질 |
CN111050803A (zh) | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
KR20200064096A (ko) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법 |
JP7404252B2 (ja) | 2017-11-08 | 2023-12-25 | ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 生体分子のコンジュゲートおよびその使用 |
TWI800552B (zh) | 2017-11-10 | 2023-05-01 | 新加坡科技研究局 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
JP7386161B2 (ja) | 2017-12-19 | 2023-11-24 | ブレイズ バイオサイエンス, インコーポレイテッド | 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法 |
WO2020113403A1 (en) | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
WO2019173832A2 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
WO2019222295A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
CA3103023A1 (en) | 2018-06-21 | 2019-12-26 | Tgw Logistics Group Gmbh | Storage and order-picking system and method for picking ordered articles |
WO2019246392A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
CN112867503A (zh) | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
WO2020065096A1 (en) | 2018-09-28 | 2020-04-02 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
WO2020086758A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
US20230045048A1 (en) | 2018-12-14 | 2023-02-09 | Proviva Therapeutics (Hong Kong) Limited | Il-15 compositions and methods of use thereof |
JP2022529943A (ja) * | 2019-04-15 | 2022-06-27 | クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
SG11202112541RA (en) | 2019-05-14 | 2021-12-30 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof |
KR20220012256A (ko) | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
US20220315909A1 (en) | 2019-06-05 | 2022-10-06 | Chugai Seiyaku Kabushiki Kaisha | Protease substrate, and polypeptide including protease cleavage sequence |
AU2020291012A1 (en) | 2019-06-12 | 2021-12-16 | AskGene Pharma, Inc. | Novel IL-15 prodrugs and methods of use thereof |
EP3997115A4 (en) | 2019-07-12 | 2023-11-22 | Proviva Therapeutics (Hong Kong) Limited | IL-2 COMPOSITIONS AND METHODS OF USE THEREOF |
EP4004026A4 (en) | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
AU2020316002A1 (en) | 2019-07-25 | 2022-03-03 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
AU2020329216A1 (en) | 2019-08-12 | 2022-02-24 | AskGene Pharma, Inc. | IL-2 fusion proteins that preferentially bind ILl-2ralpha |
EP4017594A1 (en) | 2019-08-21 | 2022-06-29 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
US20220356221A1 (en) | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
CN115315434A (zh) | 2019-12-05 | 2022-11-08 | 免疫靶向有限公司 | 白细胞介素15融合蛋白和前药及其组合物和方法 |
MX2022007202A (es) | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
JP2023510115A (ja) | 2019-12-20 | 2023-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規il2アゴニストおよびそれらの使用方法 |
BR112022013993A2 (pt) | 2020-01-15 | 2022-10-11 | Trutino Biosciences Inc | Profármacos de citocina compreendendo um ligante clivável |
AU2021240872A1 (en) | 2020-03-23 | 2022-11-17 | Zymeworks Bc Inc. | Masked IL12 fusion proteins and methods of use thereof |
US20230226202A1 (en) | 2020-03-30 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il15 compositions and methods of use thereof |
CA3172658A1 (en) | 2020-04-01 | 2021-10-07 | Raphael Rozenfeld | Masked il-15 cytokines and their cleavage products |
CA3172641A1 (en) * | 2020-04-01 | 2021-10-07 | Xilio Development, Inc. | Masked il-12 cytokines and their cleavage products |
MX2022012311A (es) | 2020-04-01 | 2023-01-05 | Xilio Dev Inc | Citocinas il-2 enmascaradas y sus productos de escisión. |
MX2022012592A (es) | 2020-04-10 | 2022-12-07 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y composiciones y metodos relacionados. |
EP4143220A4 (en) | 2020-04-30 | 2024-05-29 | Immune Targeting Inc. | COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE |
AU2021276337A1 (en) | 2020-05-19 | 2022-12-22 | Werewolf Therapeutics, Inc. | Activatable IL-12 polypeptides and methods of use thereof |
-
2022
- 2022-03-16 TW TW111109598A patent/TW202304958A/zh unknown
- 2022-03-16 EP EP22719384.4A patent/EP4308594A2/en active Pending
- 2022-03-16 IL IL305716A patent/IL305716A/en unknown
- 2022-03-16 US US17/696,222 patent/US11667687B2/en active Active
- 2022-03-16 MX MX2023010840A patent/MX2023010840A/es unknown
- 2022-03-16 JP JP2023557128A patent/JP2024511387A/ja active Pending
- 2022-03-16 AU AU2022237504A patent/AU2022237504A1/en active Pending
- 2022-03-16 WO PCT/US2022/020492 patent/WO2022197764A2/en active Application Filing
- 2022-03-16 BR BR112023018735A patent/BR112023018735A2/pt unknown
- 2022-03-16 CA CA3211924A patent/CA3211924A1/en active Pending
- 2022-03-16 KR KR1020237035206A patent/KR20230157448A/ko unknown
-
2023
- 2023-05-25 US US18/323,722 patent/US20240124546A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11667687B2 (en) | 2023-06-06 |
TW202304958A (zh) | 2023-02-01 |
WO2022197764A2 (en) | 2022-09-22 |
JP2024511387A (ja) | 2024-03-13 |
EP4308594A2 (en) | 2024-01-24 |
BR112023018735A2 (pt) | 2023-11-28 |
IL305716A (en) | 2023-11-01 |
AU2022237504A1 (en) | 2023-10-05 |
KR20230157448A (ko) | 2023-11-16 |
WO2022197764A3 (en) | 2022-11-03 |
CA3211924A1 (en) | 2022-09-22 |
US20220306717A1 (en) | 2022-09-29 |
US20240124546A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022012592A (es) | Construcciones de citocinas activables y composiciones y metodos relacionados. | |
MX2023010840A (es) | Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. | |
TW200726046A (en) | Switched converter with variable peak current and variable off-time control | |
GB2378591A (en) | RF power amplifier and methods for improving the efficiency thereof | |
WO2003047685A3 (en) | Control of arbitrary waveforms for constant delivered energy | |
CN105932970A (zh) | 包络跟踪的Doherty功率放大器 | |
MX2022002686A (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de peptidasa 30 especifica de ubiquitina (usp30). | |
BR112022022401A2 (pt) | Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade | |
WO2023060156A3 (en) | Activatable cytokine constructs and related compositions and methods | |
MX2022010542A (es) | Composiciones y metodos para reducir la expresion de citocinas. | |
ATE383084T1 (de) | Sosse auf käsebasis | |
CN102185564A (zh) | 功率放大装置及功放电路 | |
BR0208694A (pt) | Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária | |
ATE519496T1 (de) | Therapeutische anwendung von g-csf | |
MX2022012578A (es) | N-cianopirrolidinas con actividad como inhibidores de usp30. | |
CN201113924Y (zh) | 带直流偏置的二极管双平衡混频器 | |
GB672865A (en) | Improvements in and relating to radio ranging systems | |
CN202288392U (zh) | 解剖型多普勒气囊止血带 | |
AR125090A1 (es) | Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados | |
CN201499137U (zh) | 功率放大器 | |
Hsia et al. | Effect of maximum power supply voltage on envelope tracking power amplifiers using GaN HEMTs | |
CN205545167U (zh) | 双模功率放大器 | |
WO2020022627A8 (ko) | 소음순 피부 치료용 피부연고 | |
SG52727A1 (en) | Lysozyme dimer and compositions containing the same | |
WO2022192439A8 (en) | Improving immune cell function |